Skip to content
StockMarketAgent
Direct answer
CI trades against a final fair-value range of $382.18-$742.98, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs. Fair value range: low $382, high $743, with mid-point at $561.
Stock analysis

CI CI fair value $382–$743

CI
By StockMarketAgent.AI team· supervised by
已分析: 2026-05-12下次更新: 2026-08-12Methodology v2.5Review: automatedArchetype: Mature compounder
View archive
股价
$289.07
▲ +272.29 (+94.20%)
公允价值
$561
$382–$743
评级
强力买入
confidence 83/100
上行空间
+94.2%
upside to fair value
安全边际
$477.16
MoS level · 15%
市值
$76.5B
P/E fwd 8.6
英文原文ZH
翻译期间显示英文原文
此报告尚未翻译。翻译队列赶上后请在几分钟内刷新。

§1 执行摘要

  • Composite fair value $561 with high case $743.
  • Implied upside of 94.2% to fair value.
  • Moat 9/10 · confidence 83/100 · Mature compounder.
  • Trades below fair value with a meaningful cushion to the midpoint.
Fair value
$561
Margin of safety
+48.5%
Confidence
83/100
Moat
9/10

Educational analysis only — not financial advice. Always do your own due diligence.

$289.07Price
Low $382.18
Mid $561.36
High $742.98

CI trades against a final fair-value range of $382.18-$742.98, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.

  • Evernorth scale and specialty pharmacy
    Evernorth scale and specialty pharmacy dominance
  • Vertical integration of PBM and
    Vertical integration of PBM and health benefits
  • Cycle upside
    Consolidation of specialty pharmacy and managed care services driving scale efficiencies.

§2 看空情景

Sweeping legislative changes target PBM spread pricing and rebates, crippling Evernorth's profitability. At the same time, sudden medical cost inflation squeezes traditional insurance margins, limiting the cash available to service Cigna's massive debt load.

该论点可能失败的方式

PBM Spread Pricing Ban

· High

Federal legislation permanently bans spread pricing and mandates full rebate pass-throughs across all books of business.

FV impact
Moderate to Severe
Trigger
12-24 months

Medical Cost Spike

· Medium

Unanticipated structural increase in utilization rates compresses medical loss ratios beyond historical norms.

FV impact
Moderate
Trigger
6-12 months

De-leveraging Failure

· Low

Inability to service acquisition-related debt due to sustained margin compression, halting share repurchases.

FV impact
Severe
Trigger
24-36 months
需关注的早期预警信号
指标当前触发阈值
Operating margins sustainably compressing toward the 3.0% industry median over 4 consecutive quarters.MonitorDeterioration versus the report thesis
Total corporate revenue actively dropping into negative YoY growth territory.MonitorDeterioration versus the report thesis
Unplanned suspension of the share repurchase program.MonitorDeterioration versus the report thesis
Medical care ratio (MCR) exceeding internal targets for two consecutive quarters.MonitorDeterioration versus the report thesis
Key enterprise client losses within the Evernorth segment.MonitorDeterioration versus the report thesis

§3 财务历史

损益表 — 最近六期
项目T−0T−1T−2T−3T−4CAGR
期间2021-12-312022-12-312023-12-312024-12-312025-12-31Trend
营业收入$174.27B$180.03B$195.19B$244.38B+8.8%
毛利
营业利润
净利润$5.37B$6.70B$5.16B$3.43B-10.6%
每股收益(摊薄)$21.30$17.39$12.12$22.18+1.0%
EBITDA
研发
销售管理费用$13.01B$13.17B$14.82B$14.84B+3.3%

质量评分

OCF / 净利润
3.02×
>1 表示盈利质量高
会计质量门槛
Fail
经行业调整门槛
ROIC
7.2%
投入资本回报率
第 3 节

Numbers analysis

现金流

Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.

资本配置

Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.

个人订阅用户 — §4 及之后还有 11 个章节

阅读完整分析 — 还有 11 个章节。

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

涵盖每个股票的完整报告
24 个月的评级存档
关注列表简报 + 评级变更提醒
以任意语言导出 PDF + DOCX
开始免费试用
可随时取消。
FAQ

CI — frequently asked questions

  1. Based on our latest analysis, CI looks meaningfully undervalued. The current price is $289 versus a composite fair-value midpoint of $561 (range $382–$743), which implies roughly 94.2% upside to the midpoint.
Related coverage

Names readers of CI also follow

Same archetype: mature-compounder